Incidence of immune-mediated inflammatory diseases following COVID-19: a matched cohort study in UK primary care.
COVID-19
Cohort study
Immune-mediated inflammatory diseases
SARS-CoV-2
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
21 09 2023
21 09 2023
Historique:
received:
19
01
2023
accepted:
24
08
2023
medline:
25
9
2023
pubmed:
22
9
2023
entrez:
22
9
2023
Statut:
epublish
Résumé
Some patients infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) go on to experience post-COVID-19 condition or long COVID. Preliminary findings have given rise to the theory that long COVID may be due in part to a deranged immune response. In this study, we assess whether there is an association between SARS-CoV-2 infection and the incidence of immune-mediated inflammatory diseases (IMIDs). Matched cohort study using primary care electronic health record data from the Clinical Practice Research Datalink Aurum database. The exposed cohort included 458,147 adults aged 18 years and older with a confirmed SARS-CoV-2 infection and no prior diagnosis of IMIDs. They were matched on age, sex, and general practice to 1,818,929 adults with no diagnosis of confirmed or suspected SARS-CoV-2 infection. The primary outcome was a composite of any of the following IMIDs: autoimmune thyroiditis, coeliac disease, inflammatory bowel disease (IBD), myasthenia gravis, pernicious anaemia, psoriasis, rheumatoid arthritis (RA), Sjogren's syndrome, systemic lupus erythematosus (SLE), type 1 diabetes mellitus (T1DM), and vitiligo. The secondary outcomes were each of these conditions separately. Cox proportional hazard models were used to estimate adjusted hazard ratios (aHR) and 95% confidence intervals (CI) for the primary and secondary outcomes, adjusting for age, sex, ethnic group, smoking status, body mass index, relevant infections, and medications. Six hundred and nighty six (0.15%) and 2230 (0.12%) patients in the exposed and unexposed cohort developed an IMID during the follow-up period over 0.29 person-years, giving a crude incidence rate of 4.59 and 3.65 per 1000 person-years, respectively. Patients in the exposed cohort had a 22% increased risk of developing an IMID, compared to the unexposed cohort (aHR 1.22, 95% CI 1.12 to 1.33). The incidence of three IMIDs was significantly associated with SARS-CoV-2 infection. These were T1DM (aHR 1.56, 1.09 to 2.23), IBD (aHR 1.36, 1.18 to 1.56), and psoriasis (1.23, 1.05 to 1.42). SARS-CoV-2 was associated with an increased incidence of IMIDs including T1DM, IBD and psoriasis. However, these findings could be potentially due to ascertainment bias. Further research is needed to replicate these findings in other populations and to measure autoantibody profiles in cohorts of individuals with COVID-19.
Sections du résumé
BACKGROUND
Some patients infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) go on to experience post-COVID-19 condition or long COVID. Preliminary findings have given rise to the theory that long COVID may be due in part to a deranged immune response. In this study, we assess whether there is an association between SARS-CoV-2 infection and the incidence of immune-mediated inflammatory diseases (IMIDs).
METHODS
Matched cohort study using primary care electronic health record data from the Clinical Practice Research Datalink Aurum database. The exposed cohort included 458,147 adults aged 18 years and older with a confirmed SARS-CoV-2 infection and no prior diagnosis of IMIDs. They were matched on age, sex, and general practice to 1,818,929 adults with no diagnosis of confirmed or suspected SARS-CoV-2 infection. The primary outcome was a composite of any of the following IMIDs: autoimmune thyroiditis, coeliac disease, inflammatory bowel disease (IBD), myasthenia gravis, pernicious anaemia, psoriasis, rheumatoid arthritis (RA), Sjogren's syndrome, systemic lupus erythematosus (SLE), type 1 diabetes mellitus (T1DM), and vitiligo. The secondary outcomes were each of these conditions separately. Cox proportional hazard models were used to estimate adjusted hazard ratios (aHR) and 95% confidence intervals (CI) for the primary and secondary outcomes, adjusting for age, sex, ethnic group, smoking status, body mass index, relevant infections, and medications.
RESULTS
Six hundred and nighty six (0.15%) and 2230 (0.12%) patients in the exposed and unexposed cohort developed an IMID during the follow-up period over 0.29 person-years, giving a crude incidence rate of 4.59 and 3.65 per 1000 person-years, respectively. Patients in the exposed cohort had a 22% increased risk of developing an IMID, compared to the unexposed cohort (aHR 1.22, 95% CI 1.12 to 1.33). The incidence of three IMIDs was significantly associated with SARS-CoV-2 infection. These were T1DM (aHR 1.56, 1.09 to 2.23), IBD (aHR 1.36, 1.18 to 1.56), and psoriasis (1.23, 1.05 to 1.42).
CONCLUSIONS
SARS-CoV-2 was associated with an increased incidence of IMIDs including T1DM, IBD and psoriasis. However, these findings could be potentially due to ascertainment bias. Further research is needed to replicate these findings in other populations and to measure autoantibody profiles in cohorts of individuals with COVID-19.
Identifiants
pubmed: 37735654
doi: 10.1186/s12916-023-03049-5
pii: 10.1186/s12916-023-03049-5
pmc: PMC10512476
doi:
Substances chimiques
Immunomodulating Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
363Subventions
Organisme : Department of Health
Pays : United Kingdom
Organisme : Versus Arthritis
Pays : United Kingdom
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–54.
doi: 10.1038/s41579-020-00459-7
pubmed: 33024307
WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int . Accessed 19 Apr 2022.
Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155–62.
doi: 10.1097/BOR.0000000000000776
pubmed: 33332890
Burke MJ, del Rio C. Long COVID has exposed medicine’s blind-spot. Lancet Infect Dis. 2021;21(8):1062–4.
doi: 10.1016/S1473-3099(21)00333-9
pubmed: 34153235
pmcid: 8213360
Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102–7.
doi: 10.1016/S1473-3099(21)00703-9
pubmed: 34951953
National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the longterm effects of COVID-19 NICE; 2022.
Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9):e1003773.
doi: 10.1371/journal.pmed.1003773
pubmed: 34582441
pmcid: 8478214
Ayoubkhani D, Gaughan C. Updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021. Newport: Office for National Statistics; 2021.
The L. Understanding long COVID: a modern medical challenge. Lancet. 2021;398(10302):725.
doi: 10.1016/S0140-6736(21)01900-0
Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283–8.
doi: 10.1038/s41586-021-03631-y
pubmed: 34010947
Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12(570):eabd3876.
doi: 10.1126/scitranslmed.abd3876
pubmed: 33139519
pmcid: 7724273
Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881-95.e20.
doi: 10.1016/j.cell.2022.01.014
pubmed: 35216672
pmcid: 8786632
Tang K-T, Hsu B-C, Chen D-Y. Autoimmune and rheumatic manifestations associated with COVID-19 in adults: an updated systematic review. Front Immunol. 2021;12:645013.
doi: 10.3389/fimmu.2021.645013
pubmed: 33777042
pmcid: 7994612
Novelli L, Motta F, De Santis M, Ansari AA, Gershwin ME, Selmi C. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 – a systematic review of the literature. J Autoimmun. 2021;117:102592.
doi: 10.1016/j.jaut.2020.102592
pubmed: 33401171
Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis. 2021;53(10):737–54.
doi: 10.1080/23744235.2021.1924397
Kanduc D, Shoenfeld Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine. Immunol Res. 2020;68(5):310–3.
doi: 10.1007/s12026-020-09152-6
pubmed: 32946016
pmcid: 7499017
Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128(1):305–10.
doi: 10.1097/PRS.0b013e318219c171
pubmed: 21701348
pmcid: 3124652
Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol. 2019;48(6):1740-g.
doi: 10.1093/ije/dyz034
pubmed: 30859197
pmcid: 6929522
Gokhale KM, Chandan JS, Toulis K, Gkoutos G, Tino P, Nirantharakumar K. Data extraction for epidemiological research (DExtER): a novel tool for automated clinical epidemiology studies. Eur J Epidemiol. 2021;36(2):165–78.
doi: 10.1007/s10654-020-00677-6
pubmed: 32856160
Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.
doi: 10.1136/bmj.b5087
pubmed: 20228141
Agrawal A, Sridharan A, Prakash S, Agrawal H. Dendritic cells and aging: consequences for autoimmunity. Expert Rev Clin Immunol. 2012;8(1):73–80.
doi: 10.1586/eci.11.77
pubmed: 22149342
pmcid: 3285507
Amador-Patarroyo MJ, Rodriguez-Rodriguez A, Montoya-Ortiz G. How does age at onset influence the outcome of autoimmune diseases? Autoimmune Dis. 2012;2012:251730.
pubmed: 22195277
Beeson PB. Age and sex associations of 40 autoimmune diseases. Am J Med. 1994;96(5):457–62.
doi: 10.1016/0002-9343(94)90173-2
pubmed: 8192178
Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol. 2008;173(3):600–9.
doi: 10.2353/ajpath.2008.071008
pubmed: 18688037
pmcid: 2527069
Calixto OJ, Anaya JM. Socioeconomic status. The relationship with health and autoimmune diseases. Autoimmun Rev. 2014;13(6):641–54.
doi: 10.1016/j.autrev.2013.12.002
pubmed: 24418307
Versini M, Jeandel P-Y, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev. 2014;13(9):981–1000.
doi: 10.1016/j.autrev.2014.07.001
pubmed: 25092612
Costenbader KH, Karlson EW. Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Lupus. 2006;15(11):737–45.
doi: 10.1177/0961203306069344
pubmed: 17153844
Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2(3):119–25.
doi: 10.1016/S1568-9972(03)00006-5
pubmed: 12848952
Moroni L, Bianchi I, Lleo A. Geoepidemiology, gender and autoimmune disease. Autoimmun Rev. 2012;11(6):A386–92.
doi: 10.1016/j.autrev.2011.11.012
pubmed: 22142547
Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM. Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms. Viruses. 2019;11(8):762.
doi: 10.3390/v11080762
pubmed: 31430946
pmcid: 6723519
Hussein HM, Rahal EA. The role of viral infections in the development of autoimmune diseases. Crit Rev Microbiol. 2019;45(4):394–412.
doi: 10.1080/1040841X.2019.1614904
pubmed: 31145640
Araújo-Fernández S, Ahijón-Lana M, Isenberg DA. Drug-induced lupus: including anti-tumour necrosis factor and interferon induced. Lupus. 2014;23(6):545–53.
doi: 10.1177/0961203314523871
pubmed: 24557776
Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf. 2011;34(5):357–74.
doi: 10.2165/11588500-000000000-00000
pubmed: 21513360
National Institute for Health and Care Excellence (NICE). Obesity: identifying, assessing and managing obesity in adults, young people and children. 2014. https://www.nice.org.uk/guidance/cg189 . Accessed 25 Apr 2022
Nassar M, Nso N, Baraka B, Alfishawy M, Mohamed M, Nyabera A, et al. The association between COVID-19 and type 1 diabetes mellitus: a systematic review. Diabetes Metab Syndr. 2021;15(1):447–54.
doi: 10.1016/j.dsx.2021.02.009
pubmed: 33592371
pmcid: 7872855
Taplin CE, Barker JM. Autoantibodies in type 1 diabetes. Autoimmunity. 2008;41(1):11–8.
doi: 10.1080/08916930701619169
pubmed: 18176860
ten Bergen LL, Petrovic A, Aarebrot AK, Appel S. Current knowledge on autoantigens and autoantibodies in psoriasis. Scand J Immunol. 2020;92(4):e12945.
doi: 10.1111/sji.12945
pubmed: 32697368
Joossens S, Vermeire S, Van Steen K, Godefridis G, Claessens G, Pierik M, et al. Pancreatic autoantibodies in inflamm bowel dis. Inflamm Bowel Dis. 2004;10(6):771–7.
doi: 10.1097/00054725-200411000-00012
pubmed: 15626896
Brown J, Kirke-Wade E. Coronavirus: a history of English lockdown laws. London: The Commons Library. 2021. https://commonslibrary.parliament.uk/research-briefings/cbp-9068/ . Accessed 17 Aug 2023.
House of Commons Health and Social Care Committee. Clearing the backlog caused by the pandemic. London: UK Parliament; 2021. https://committees.parliament.uk/publications/8352/documents/85020/default . Accessed 18 Aug 2023
Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228–33.
doi: 10.1172/JCI78088
pubmed: 25893595
pmcid: 4518692
Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1706–14.
doi: 10.1038/s41591-022-01909-w
pubmed: 35879616
pmcid: 9388369
UK Health Security Agency. The effectiveness of vaccination against long COVID A rapid evidence briefing. London: UK HSA; 2022. https://www.icpcovid.com/sites/default/files/2022-02/Ep%20241-9%20UK%20Health%20Security%20Agency%20The%20effectiveness%20of%20vaccination%20against%20long%20COVID%20Feb%202022.pdf . Accessed 18 Aug 2023